Skip to main content
Premium Trial:

Request an Annual Quote

Strata Oncology: Sundu Brahmasandra

Strata Oncology appointed Sundu Brahmasandra as chief operating officer. Brahmasandra previously served as president and COO of NeuMoDx Molecular, and later as vice president and head of operations and product management at Qiagen, after that company acquired NeuMoDx. He also cofounded HandyLab, a developer and manufacturer of molecular diagnostic assays and automation platforms, which was acquired by BD Diagnostics, where he then served as vice president of R&D assay development. 

Brahmasandra holds a PhD in chemical engineering from the University of Michigan College of Engineering and a bachelor's degree in chemical engineering from the Indian Institute of Technology, Madras.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.